These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 16140106

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA, López Tarruella S, García Paredes B, Rodríguez Lajusticia L, Villalobos L, Díaz Rubio E.
    Med Oral Patol Oral Cir Bucal; 2007 Sep 01; 12(5):E351-6. PubMed ID: 17767097
    [Abstract] [Full Text] [Related]

  • 3. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.
    J Clin Oncol; 2005 Dec 01; 23(34):8580-7. PubMed ID: 16314620
    [Abstract] [Full Text] [Related]

  • 4. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
    Smith A, Kressley A, Saif MW.
    JOP; 2009 Mar 09; 10(2):212-4. PubMed ID: 19287122
    [No Abstract] [Full Text] [Related]

  • 5. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE, Sawatari Y, Fortin M, Broumand V.
    J Oral Maxillofac Surg; 2005 Nov 09; 63(11):1567-75. PubMed ID: 16243172
    [Abstract] [Full Text] [Related]

  • 6. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
    Friedrich RE, Blake FA.
    Anticancer Res; 2007 Nov 09; 27(4A):1841-5. PubMed ID: 17649782
    [Abstract] [Full Text] [Related]

  • 7. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug 09; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 8. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.
    Eur Urol; 2008 Nov 09; 54(5):1066-72. PubMed ID: 18602738
    [Abstract] [Full Text] [Related]

  • 9. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
    Ortega C, Montemurro F, Faggiuolo R, Vormola R, Nanni D, Goia F, Gilardino MO, Aglietta M.
    Acta Oncol; 2007 Nov 09; 46(5):664-8. PubMed ID: 17562443
    [Abstract] [Full Text] [Related]

  • 10. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
    Brown JJ, Ramalingam L, Zacharin MR.
    Clin Endocrinol (Oxf); 2008 Jun 09; 68(6):863-7. PubMed ID: 18221397
    [Abstract] [Full Text] [Related]

  • 11. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.
    Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, Diaz JM, Scully C.
    Oral Oncol; 2006 Mar 09; 42(3):327-9. PubMed ID: 16275156
    [No Abstract] [Full Text] [Related]

  • 12. Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case.
    Frei M, Bornstein MM, Schaller B, Reichart PA, Weimann R, Iizuka T.
    J Oral Maxillofac Surg; 2010 Apr 09; 68(4):863-7. PubMed ID: 20307770
    [No Abstract] [Full Text] [Related]

  • 13. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
    Jimenez-Soriano Y, Bagan JV.
    Med Oral Patol Oral Cir Bucal; 2005 Jul 01; 10 Suppl 2():E88-91. PubMed ID: 15995577
    [No Abstract] [Full Text] [Related]

  • 14. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV, Rodrigues JM, Cavaleiro MV, Lobato JM, Xavier L, Santos JD, Maurício AC.
    Acta Med Port; 2007 Jul 01; 20(2):185-92. PubMed ID: 17868526
    [Abstract] [Full Text] [Related]

  • 15. Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series.
    Ferlito S, Liardo C, Puzzo S.
    Minerva Stomatol; 2010 Jul 01; 59(11-12):593-601. PubMed ID: 21217623
    [Abstract] [Full Text] [Related]

  • 16. Complication related to bisphosphonate therapy: osteonecrosis of the jaw.
    Lee J.
    J Infus Nurs; 2009 Jul 01; 32(6):330-5. PubMed ID: 19918142
    [Abstract] [Full Text] [Related]

  • 17. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
    Kraj M, Pogłód R, Maj S, Owczarska K.
    Acta Pol Pharm; 2006 Jul 01; 63(5):450-2. PubMed ID: 17357613
    [No Abstract] [Full Text] [Related]

  • 18. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE, Umland EM.
    Pharmacotherapy; 2008 May 01; 28(5):667-77. PubMed ID: 18447663
    [Abstract] [Full Text] [Related]

  • 19. Jaw complications in breast and prostate cancer patients treated with zoledronic acid.
    Ortega C, Faggiuolo R, Vormola R, Montemurro F, Nanni D, Goia F, Aglietta M.
    Acta Oncol; 2006 May 01; 45(2):216-7. PubMed ID: 16546871
    [No Abstract] [Full Text] [Related]

  • 20. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS, Fayans EP.
    Todays FDA; 2008 Aug 01; 20(8):38-41, 43-6. PubMed ID: 18767452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.